αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: A preclinical study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 2, 2011, Pages 323-333

  Aide, Nicolas ^a,b,e   Briand, Mélanie ^a   Bohn, Pierre ^c   Dutoit, Soizic ^a   Lasnon, Charline ^b   Chasle, Jacques ^a   Rouvet, Jean ^c   Modzelewski, Romain ^c   Vela, Antony ^a   Deslandes, Edwiges ^a   Vera, Pierre ^c   Poulain, Laurent ^a   Carreiras, Franck ^d  

^a UNIVERSITÉ DE CAEN   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE CERGY PONTOISE   (France)

^e CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

v 3 expression; 18F FDG; Mature teratoma; Non seminomatous germ cell tumour; Residual masses

Indexed keywords

6 HYDRAZINONICOTINIC ACID ARGINYLGLYCYLASPARTIC ACID DEXTRO PHENYLALANYLLYSINE TC 99M; CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; RETINOIC ACID; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CLINICAL ASSESSMENT; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG MEGADOSE; DRUG UPTAKE; EMBRYONAL CARCINOMA; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INJECTION; LOW DRUG DOSE; MALE; MESENCHYME CELL; MICRO-COMPUTED TOMOGRAPHY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MUSCLE; NECROSIS; NONHUMAN; NONSEMINOMATOUS GERM CELL TUMOR; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARDIZED UPTAKE VALUE; TERATOMA; TREATMENT DURATION; TUMOR XENOGRAFT;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MOLECULAR IMAGING; NECROSIS; NEOPLASM, RESIDUAL; RATS; TERATOMA; TESTICULAR NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TRETINOIN;

EID: 79551527230     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1624-9     Document Type: Article

References (46)

1. C Kollmannsberger F Honecker C Bokemeyer 2006 Treatment of germ cell tumors-update 2006 Ann Oncol 17 Suppl 10 x31 x35 10.1093/annonc/mdl232 17018745 (Pubitemid 44541982)
2. M De Santis A Becherer C Bokemeyer F Stoiber K Oechsle F Sellner, et al. 2004 2-18Fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial J Clin Oncol 22 1034 1039 10.1200/JCO.2004.07.188 15020605 (Pubitemid 41095035)
3. JT Hartmann HJ Schmoll MA Kuczyk M Candelaria C Bokemeyer 1997 Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors Ann Oncol 8 531 538 1:STN:280:DyaK2svgsVyisQ%3D%3D 10.1023/A:1008200425854 9261521 (Pubitemid 27359416)
4. S Krege J Beyer R Souchon P Albers W Albrecht F Algaba, et al. 2008 European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I Eur Urol 53 478 496 10.1016/j.eururo.2007.12.024 18191324
5. S Krege J Beyer R Souchon P Albers W Albrecht F Algaba, et al. 2008 European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II Eur Urol 53 497 513 10.1016/j.eururo.2007.12.025 18191015
6. JT Hartmann M Candelaria MA Kuczyk HJ Schmoll C Bokemeyer 1997 Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours Eur J Cancer 33 843 847 1:STN:280:DyaK2svjslaksg%3D%3D 10.1016/S0959-8049(96)00517-5 9291803 (Pubitemid 27287033)
7. P Bourguet MP Blanc-Vincent A Boneu L Bosquet B Chauffert C Corone, et al. 2003 Summary of the standards, options and recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002) Br J Cancer 89 Suppl 1 S84 S91 10.1038/sj.bjc. 6601088 12915907 (Pubitemid 37076153)
8. JR Spermon LF Geus-Oei LA Kiemeney JA Witjes WJ Oyen 2002 The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours BJU Int 89 549 556 1:CAS:528:DC%2BD38XjslSqtr8%3D 10.1046/j.1464-410X.2002.02641.x 11942962 (Pubitemid 34948297)
9. D Sanchez JJ Zudaire JM Fernandez J Lopez J Arocena G Sanz, et al. 2002 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse BJU Int 89 912 916 1:STN:280:DC%2BD383ntV2iug%3D%3D 10.1046/j.1464-410X.2002.02779.x 12010239 (Pubitemid 34535427)
10. C Kollmannsberger K Oechsle BM Dohmen A Pfannenberg R Bares CD Claussen, et al. 2002 Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma Cancer 94 2353 2362 10.1002/cncr.10494 12015760 (Pubitemid 34457116)
11. L Johns Putra N Lawrentschuk Z Ballok A Hannah A Poon A Tauro, et al. 2004 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy Urology 64 1202 1207 1:STN:280: DC%2BD2cnitF2ntQ%3D%3D 10.1016/j.urology.2004.07.024 15596197 (Pubitemid 39650924)
12. SF Hain MJ O'Doherty AR Timothy MD Leslie PG Harper RA Huddart 2000 Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse Br J Cancer 83 863 869 10.1054/bjoc.2000.1389 1:STN:280:DC%2BD3cvmvFarsQ%3D%3D 10.1054/bjoc.2000.1389 10970686
13. U Cremerius PJ Effert G Adam O Sabri M Zimmy G Wagenknecht, et al. 1998 FDG PET for detection and therapy control of metastatic germ cell tumor J Nucl Med 39 815 822 1:STN:280:DyaK1c3lt1amtA%3D%3D 9591582
14. F Cao Z Li A Lee Z Liu K Chen H Wang, et al. 2009 Noninvasive de novo imaging of human embryonic stem cell-derived teratoma formation Cancer Res 69 2709 2713 10.1158/0008-5472.CAN-08-4122 1:CAS:528:DC%2BD1MXjvVWju70%3D 10.1158/0008-5472.CAN-08-4122 19318556
15. JD Hood DA Cheresh 2002 Role of integrins in cell invasion and migration Nat Rev Cancer 2 91 100 10.1038/nrc72710.1038/nrc727 10.1038/nrc727 12635172
16. A Howe AE Aplin SK Alahari RL Juliano 1998 Integrin signaling and cell growth control Curr Opin Cell Biol 10 220 231 1:CAS:528:DyaK1cXisFyntLs%3D 10.1016/S0955-0674(98)80144-0 9561846 (Pubitemid 28174764)
17. RO Hynes JC Lively JH McCarty D Taverna SE Francis K Hodivala-Dilke, et al. 2002 The diverse roles of integrins and their ligands in angiogenesis Cold Spring Harb Symp Quant Biol 67 143 153 1:CAS:528:DC%2BD3sXltlGhu7c%3D 10.1101/sqb.2002.67.143 12858535
18. PC Brooks AM Montgomery M Rosenfeld RA Reisfeld T Hu G Klier, et al. 1994 Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 1157 1164 10.1016/0092-8674(94) 90007-8 1:CAS:528:DyaK2MXivVWqu7o%3D 10.1016/0092-8674(94)90007-8 7528107
19. F Carreiras M Lehmann F Sichel J Marvaldi P Gauduchon JY Le Talaer 1995 Implication of the alpha v beta 3 integrin in the adhesion of the ovarian-adenocarcinoma cell line IGROV1 Int J Cancer 63 530 536 1:CAS:528:DyaK28Xkslemtg%3D%3D 10.1002/ijc.2910630413 7591263
20. F Carreiras B Thiébot J Leroy-Dudal S Maubant MF Breton H Darbeida 2002 Involvement of alphavbeta 3 integrin and disruption of endothelial fibronectin network during the adhesion of the human ovarian adenocarcinoma cell line IGROV1 on the human umbilical vein cell extracellular matrix Int J Cancer 99 800 808 10.1002/ijc.10433 10.1002/ijc.10433 1:CAS:528:DC%2BD38XksVajs70%3D 10.1002/ijc.10433 12115480 (Pubitemid 34575696)
21. C Decristoforo I Santos HJ Pietzsch JU Kuenstler A Duatti CJ Smith, et al. 2007 Comparison of in vitro and in vivo properties of [99mTc]cRGD peptides labeled using different novel Tc-cores Q J Nucl Med Mol Imaging 51 33 41 1:STN:280:DC%2BD2s7nsVWqsQ%3D%3D 17372571
22. M Janssen WJ Oyen LF Massuger C Frielink I Dijkgraaf DS Edwards, et al. 2002 Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting Cancer Biother Radiopharm 17 641 646 10.1089/108497802320970244 10.1089/108497802320970244 1:CAS:528:DC%2BD3sXovVWmug%3D%3D 10.1089/ 108497802320970244 12537667
23. KH Jung KH Lee JY Paik BH Ko JS Bae BC Lee, et al. 2006 Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy J Nucl Med 47 2000 2007 1:CAS:528: DC%2BD2sXksFKgug%3D%3D 17138743
24. L Sancey V Ardisson LM Riou M Ahmadi D Marti-Batlle D Boturyn, et al. 2007 In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD Eur J Nucl Med Mol Imaging 34 2037 2047 10.1007/s00259-007-0497-z 10.1007/s00259-007-0497-z 1:CAS:528: DC%2BD2sXhtlyiur%2FF 10.1007/s00259-007-0497-z 17674000 (Pubitemid 350212119)
25. ZF Su G Liu S Gupta Z Zhu M Rusckowski DJ Hnatowich 2002 In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging Bioconjug Chem 13 561 570 10.1021/bc0155566 1:CAS:528:DC%2BD38XivFCgsb8%3D 10.1021/bc0155566 12009947 (Pubitemid 34527518)
26. M Ahmadi L Sancey A Briat L Riou D Boturyn P Dumy, et al. 2008 Chemical and biological evaluations of an (111)In-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model Cancer Biother Radiopharm 23 691 700 10.1089/cbr.2008.0528 1:CAS:528:DC%2BD1MXpsVaitw%3D%3D 10.1089/cbr.2008.0528 19111043
27. R Haubner AJ Beer H Wang X Chen 2010 Positron emission tomography tracers for imaging angiogenesis Eur J Nucl Med Mol Imaging 37 Suppl 1 S86 S103 10.1007/s00259-010-1503-4 10.1007/s00259-010-1503-4 20559632
28. PW Andrews I Damjanov D Simon GS Banting C Carlin NC Dracopoli, et al. 1984 Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro Lab Invest 50 147 162 1:CAS:528:DyaL2cXhsFCgu70%3D 6694356
29. N Aide L Poulain M Briand S Dutoit S Allouche A Labiche, et al. 2009 Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease Eur J Nucl Med Mol Imaging 36 396 405 10.1007/s00259-008-0984-x 10.1007/s00259-008-0984-x 1:CAS:528: DC%2BD1MXhvF2ru7o%3D 10.1007/s00259-008-0984-x 19050878
30. A Rosset L Spadola O Ratib 2004 OsiriX: an open-source software for navigating in multidimensional DICOM images J Digit Imaging 17 205 216 10.1007/s10278-004-1014-6 10.1007/s10278-004-1014-6 10.1007/s10278-004-1014-6 15534753 (Pubitemid 40378992)
31. N Kieffer DR Phillips 1990 Platelet membrane glycoproteins: functions in cellular interactions Annu Rev Cell Biol 6 329 357 1:CAS:528:DyaK3MXit1Kiuro%3D 10.1146/annurev.cb.06.110190.001553 2275816
32. MF Lutke Holzik HJ Hoekstra NH Mulder AJ Suurmeijer DT Sleijfer JA Gietema 2003 Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor Ann Surg Oncol 10 131 135 10.1245/ASO.2003.05.024 12620907 (Pubitemid 40485932)
33. N Aide F Comoz E Sevin 2007 Enlarging residual mass after treatment of a nonseminomatous germ cell tumor: growing teratoma syndrome or cancer recurrence? J Clin Oncol 25 4494 4496 10.1200/JCO.2007.12.7530 17906212 (Pubitemid 350013857)
34. PE Spiess W Kassouf GA Brown AM Kamat P Liu JA Gomez, et al. 2007 Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience J Urol 177 1330 1334 10.1016/j.juro.2006.11.086 17382725 (Pubitemid 46435982)
35. Y Mizutani N Sato A Kawauchi N Nonomura M Fukushima T Miki 2002 Cisplatin-induced in vivo differentiation of human embryonal carcinoma BJU Int 89 454 458 1:CAS:528:DC%2BD38XjtFakt70%3D 10.1046/j.1464-4096.2001.01794.x 11872042 (Pubitemid 34304376)
36. S Wouda B Timmer NH Mulder A Dam J Koudstaal JW Oosterhuis 1993 Retinoic acid and cisdiaminodichloroplatinum in the treatment of murine teratocarcinomas in vivo in a nullipotent model J Immunother Emphasis Tumor Immunol 13 261 266 1:CAS:528:DyaK2cXjtFGgsrk%3D 8334110
37. JW Oosterhuis AJ Suurmeyer DT Sleyfer HS Koops J Oldhoff G Fleuren 1983 Effects of multiple-drug chemotherapy (cis-diammine-dichloroplatinum, bleomycin, and vinblastine) on the maturation of retroperitoneal lymph node metastases of nonseminomatous germ cell tumors of the testis. No evidence for de novo induction of differentiation Cancer 51 408 416 1:STN:280:DyaL3s7gt1OhsQ%3D%3D 10.1002/1097-0142(19830201)51:3<408::AID-CNCR2820510309>3.0.CO;2-4 6185202 (Pubitemid 13185367)
38. WK Hong RE Wittes ST Hajdu E Cvitkovic WF Whitmore RB Golbey 1977 The evolution of mature teratoma from malignant testicular tumors Cancer 40 2987 2992 1:STN:280:DyaE1c%2Fmt1ClsQ%3D%3D 10.1002/1097-0142(197712)40:6<2987:: AID-CNCR2820400634>3.0.CO;2-A 563283
39. SM Castedo B de Jong JW Oosterhuis VJ Idenburg R Seruca J Buist, et al. 1989 Chromosomal changes in mature residual teratomas following polychemotherapy Cancer Res 49 672 676 1:STN:280:DyaL1M%2FovFKgsA%3D%3D 2910486
40. MJ Reinhardt VG Müller-Mattheis CD Gerharz HR Vosberg R Ackermann HW Müller-Gärtner 1997 FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy J Nucl Med 38 99 101 1:STN:280:DyaK2s7lt1ahug%3D%3D 8998160
41. C Pfannenberg P Aschoff H Dittmann F Mayer G Reischl C von Weyhern, et al. 2010 PET/CT with 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors? J Nucl Med 51 845 853 10.2967/jnumed.109.070425 20484416
42. S Connor P Guest 1999 Conversion of multiple solid testicular teratoma metastases to fatty and cystic liver masses following chemotherapy: CT evidence of "maturation" Br J Radiol 72 1114 1116 1:STN:280: DC%2BD3c7msFKmug%3D%3D 10700831
43. DM Panicek GC Toner RT Heelan GJ Bosl 1990 Nonseminomatous germ cell tumors: enlarging masses despite chemotherapy Radiology 175 499 502 1:STN:280:DyaK3c3it1Gitg%3D%3D 2158120
44. PC Stomper MS Jochelson MB Garnick JP Richie 1985 Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: correlation of CT and histology AJR Am J Roentgenol 145 743 746 1:STN:280:DyaL2MzgtlOqtA%3D%3D 3875994
45. BS Carver FJ Bianco Jr B Shayegan A Vickers RJ Motzer GJ Bosl, et al. 2006 Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection J Urol 176 100 103 10.1016/S0022-5347(06)00508-8 10.1016/S0022-5347(06)00508-8 16753380 discussion 103-4 (Pubitemid 43815381)
46. Y Sugawara K Zasadny HB Grossman IR Francis MF Clarke RL Wahl 1999 Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling Radiology 211 249 255 1:STN:280:DyaK1M3gsFCkug%3D%3D 10189480